Relay Therapeutics Company Insiders

RLAY Stock  USD 3.71  0.08  2.20%   
Relay Therapeutics' insiders are aggressively selling. The analysis of the overall insider sentiment regarding Relay Therapeutics suggests that vertually all insiders are panicking. Relay Therapeutics employs about 259 people. The company is managed by 15 executives with a total tenure of roughly 605 years, averaging almost 40.0 years of service per executive, having 17.27 employees per reported executive.

Insider Sentiment 0

 Mostly Selling

 
Selling
 
Buying

Latest Trades

2025-07-09Sanjiv PatelDisposed 61379 @ 3.57View
2025-04-30Thomas CatinazzoDisposed 12943 @ 3View
2025-04-28Thomas CatinazzoDisposed 2690 @ 3.17View
2025-04-23Sanjiv PatelDisposed 61422 @ 2.97View
2025-03-27Thomas CatinazzoDisposed 4864 @ 2.84View
2025-02-13Sanjiv PatelDisposed 75324 @ 3.7View
2025-02-11Sanjiv PatelDisposed 140182 @ 3.85View
2025-01-30Peter RahmerDisposed 17250 @ 4.42View
2025-01-28Peter RahmerDisposed 1673 @ 4.63View
2025-01-22Sanjiv PatelDisposed 125000 @ 4.8View
2025-01-06Peter RahmerDisposed 16576 @ 4.45View
2025-01-02Peter RahmerDisposed 32156 @ 4.15View
2024-12-27Thomas CatinazzoDisposed 4865 @ 4.42View
2024-12-16Sanjiv PatelDisposed 100000 @ 5View
Monitoring Relay Therapeutics' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Relay Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
For more information on how to buy Relay Stock please use our How to Invest in Relay Therapeutics guide.

Relay Therapeutics' Workforce Through the Years

Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Relay Therapeutics' future performance. Based on our forecasts, it is anticipated that Relay will maintain a workforce of slightly above 260 employees by August 2025.
 
Covid

Relay Therapeutics Management Team Effectiveness

The company has return on total asset (ROA) of (0.2882) % which means that it has lost $0.2882 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4546) %, meaning that it created substantial loss on money invested by shareholders. Relay Therapeutics' management efficiency ratios could be used to measure how well Relay Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.41 in 2025. Return On Capital Employed is likely to drop to -0.48 in 2025. At this time, Relay Therapeutics' Net Tangible Assets are fairly stable compared to the past year. Other Current Assets is likely to rise to about 29.3 M in 2025, whereas Total Assets are likely to drop slightly above 855.6 M in 2025.
Common Stock Shares Outstanding is likely to drop to about 89.5 M in 2025. Net Loss is likely to drop to about (274.5 M) in 2025

Relay Therapeutics Workforce Comparison

Relay Therapeutics is rated fifth in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 2,974. Relay Therapeutics holds roughly 259 in number of employees claiming about 9% of equities under Health Care industry.

Relay Therapeutics Insider Trading History

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Relay Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Relay Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Relay Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Covid
Buy/Sell Ratio# Purchases Trades# Sales TradesTotal Shares PurchasedTotal Shares Sold
2025-06-01
0.75
9
12
 1,251,327 
 138,865 
2025-03-01
0.4
10
25
 3,256,288 
 917,139 
2024-09-01
0.1176
2
17
 86,706 
 238,532 
2024-06-01
0.7692
10
13
 762,033 
 141,061 
2024-03-01
0.625
5
8
 1,662,360 
 10,522 
2023-06-01
0.8462
11
13
 628,755 
 25,881 
2023-03-01
0.6842
13
19
 1,819,340 
 211,645 
2022-12-01
0.2857
6
21
 72,000 
 222,360 
2022-09-01
0.1481
4
27
 137,138 
 253,984 
2022-06-01
1.25
15
12
 530,978 
 59,543 
2022-03-01
0.6875
11
16
 1,046,120 
 115,097 
2021-12-01
0.3077
4
13
 30,316 
 308,947 
2021-09-01
0.2857
2
7
 29,000 
 59,232 
2021-06-01
0.8333
10
12
 173,742 
 213,370 
2021-03-01
0.7368
14
19
 854,905 
 5,872,394 
2020-09-01
0.3
15
50
 45,728,592 
 152,763,974 

Relay Therapeutics Notable Stakeholders

A Relay Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Relay Therapeutics often face trade-offs trying to please all of them. Relay Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Relay Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.

About Relay Therapeutics Management Performance

The success or failure of an entity such as Relay Therapeutics often depends on how effective the management is. Relay Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Relay management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Relay management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.39)(0.41)
Return On Capital Employed(0.45)(0.48)
Return On Assets(0.39)(0.41)
Return On Equity(0.43)(0.41)
Please note, the imprecision that can be found in Relay Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Relay Therapeutics. Check Relay Therapeutics' Beneish M Score to see the likelihood of Relay Therapeutics' management manipulating its earnings.

Relay Therapeutics Workforce Analysis

Traditionally, organizations such as Relay Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Relay Therapeutics within its industry.

Relay Therapeutics Manpower Efficiency

Return on Relay Therapeutics Manpower

Revenue Per Employee38.6K
Revenue Per Executive667.1K
Net Loss Per Employee1.3M
Net Loss Per Executive22.5M
Working Capital Per Employee2.9M
Working Capital Per Executive50.6M

Additional Tools for Relay Stock Analysis

When running Relay Therapeutics' price analysis, check to measure Relay Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Relay Therapeutics is operating at the current time. Most of Relay Therapeutics' value examination focuses on studying past and present price action to predict the probability of Relay Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Relay Therapeutics' price. Additionally, you may evaluate how the addition of Relay Therapeutics to your portfolios can decrease your overall portfolio volatility.